Keywords: بورتِـزومیب; CCI; Charlson Comorbidity Index; MM; multiple myeloma; NHIRD; National Health Insurance Research Database; RCI; Registry of Catastrophic Illness; Multiple myeloma; Epidemiology; Bortezomib; Incidence; Prevalence; Mortality; Asia;
مقالات ISI بورتِـزومیب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: بورتِـزومیب; Dolor; NeuropatÃa periférica; Bortezomib; Mieloma múltiple; Detección precoz; Repercusiones en las Actividades de la vida diaria; Pain; Peripheral neuropathy; Bortezomib; Multiple myeloma; Early detection; Effects on Activities of daily living;
Keywords: بورتِـزومیب; Acute pancreatitis; Proteasome; NF-κB; Bortezomib;
Keywords: بورتِـزومیب; Red blood cell distribution width; Multiple myeloma; Prognosis; Bortezomib;
Keywords: بورتِـزومیب; Mantle cell lymphoma; Ibrutinib; Novel therapies; Bruton's tyrosine kinase inhibitors; Bortezomib; Lenalidomide; Relapsed; Refractory; Ibrutinib combinations;
Keywords: بورتِـزومیب; Multiple myeloma; Toxic death; Early mortality; Newly diagnosed; Transplant-Ineligible; New drugs; Bortezomib; Lenalidomide; Thalidomide;
Keywords: بورتِـزومیب; Bortezomib; CAM-DR; Dexamethasone; IL-6;
Keywords: بورتِـزومیب; Multiple myeloma; Bortezomib; Carfilzomib; Proteasome inhibitor;
Keywords: بورتِـزومیب; Autologous stem cell transplantation; Bortezomib; High-risk; Multiple myeloma; t(4;14);
Keywords: بورتِـزومیب; BTZ; bortezomib; CFZ; carfilzomib; C-L; caspase-like; CNS; central nervous system; CT-L; chymotrypsin-like; CYPs; cytochrome P450 enzymes; iP; immunoproteasome; IXZ; ixazomib; MM; multiple myeloma; OPZ; oprozomib; PD; pharmacodynamic; PI; proteasome inhib
Keywords: بورتِـزومیب; Bortezomib; Daratumumab; Dexamethasone; Epigenetic aberrations; Immunomodulatory drugs; Lenalidomide; Microenvironment; P-glycoprotein; Proteasome inhibitors;
Keywords: بورتِـزومیب; Bortezomib; Global; Observational study; Routine practice; Stem cell transplantation;
Keywords: بورتِـزومیب; proteasome inhibitors; multiple myeloma; bortezomib; ubiquitin-proteasome pathway;
Keywords: بورتِـزومیب; myeloma treatment; carfilzomib; bortezomib; toxicity;
Keywords: بورتِـزومیب; Kidney transplantation; multiple myeloma; autologous stem cell transplantation (ASCT); outcomes; end-stage renal disease (ESRD); kidney failure; renal replacement therapy (RRT); RRT modality; hematologic malignancy; light chain deposition disease (LCDD);
Keywords: بورتِـزومیب; Light chain amyloidosis; Organ response, chemotherapy; Bortezomib; Transplantation;
Keywords: بورتِـزومیب; Plasmablastic lymphoma; Bortezomib; Survival; Systematic review;
Keywords: بورتِـزومیب; Bortezomib; BTK; Clinical trial; Copanlisib; Ibritumomab tiuxetan; Ibrutinib; Idelalisib; Lenalidomide; Marginal zone lymphoma; Obinutuzumab; PI3K; Radioimmunotherapy; Rituximab; TGR-1202; Ublituximab; Venetoclax;
Keywords: بورتِـزومیب; Bortezomib; Multiple myeloma; Proteasome activity; PSMB1; SNP;
Keywords: بورتِـزومیب; Neuropathy; Stem cells; IPSC-derived neurons; Taxanes; Platinating agents; Bortezomib; Thalidomide; Goshajinkigan;
Keywords: بورتِـزومیب; Cardiac amyloidosis; light chain amyloidosis; heart transplantation; autologous; stem cell transplantation; bortezomib;
Keywords: بورتِـزومیب; AIF; apoptosis inducing factor; Ang; angiopoietin; AP-1; activator protein-1; APEX; Assessment of Proteasome Inhibition for Extending Remissions; ATP; adenosine-5â²-triphosphate; BiPN; bortezomib-induced peripheral neuropathy; CiPN; chemotherapy-induced
Keywords: بورتِـزومیب; Bortezomib; del(13q); del(17p); t(4;14); t(14;16)
Keywords: بورتِـزومیب; apoptosis; autophagy; bortezomib; proteasome inhibitors; solid tumors
Keywords: بورتِـزومیب; Bortezomib; Epidemiology; Kaposi sarcoma-associated herpesvirus; Management; Outcomes; Primary effusion lymphoma
Keywords: بورتِـزومیب; Bortezomib; High-risk myeloma; Lenalidomide; Maintenance therapy; RVD maintenance
Keywords: بورتِـزومیب; Bortezomib; HDM/SCT; Melphalan; Overall survival; Treatment response
Keywords: بورتِـزومیب; bortezomib; congestive heart failure; cyclophosphamide; infiltrative cardiomyopathy; light chain; melphalan; AL; immunoglobulin light chain; BDex+AA; bortezomib, dexamethasone, and alkylating agent; CI; confidence interval; dFLC; free light-chain differen
Keywords: بورتِـزومیب; Multiple myeloma; Translantation; Allogeneic; Bortezomib; Immunomodulatory drugs;
Keywords: بورتِـزومیب; biopsy; bortezomib; cardiac amyloidosis; light-chain amyloidosis; NT-proBNP;
Keywords: بورتِـزومیب; Heart transplantation; Heart transplant allocation; Primary graft dysfunction; Sensitization; Rituximab; Bortezomib; Eculizumab;
Keywords: بورتِـزومیب; Rituximab; Ibrutinib; Bortezomib; Carfilzomib; Fludarabine;
Keywords: بورتِـزومیب; Heparanase; Chemotherapy; Multiple myeloma; Proteasome inhibitors; NF-κB; Roneparstat; HPSE; heparanase; (NF-κB); nuclear factor-kappa B; SDC1; syndecan-1; BTZ; bortezomib; CFZ; carfilzomib; HGF; hepatocyte growth factor; VEGF; vascular endothelial grow
Keywords: بورتِـزومیب; Mantle cell; Stem cell transplantation; Maintenance; MRD; Novel therapies; Bortezomib; Ibrutinib; Lenalidomide;
Keywords: بورتِـزومیب; szpiczak plazmocytowy; niewydolność nerek; talidomid; lenalidomid; bortezomib; karfilzomibMultiple myeloma; Renal insufficiency; Thalidomide; Lenalidomide; Bortesomib; Carfilzomib
Keywords: بورتِـزومیب; Amiloidosis; Cadenas ligeras libres; Fragmento aminoterminal del péptido natriurético cerebral; Bortezomib; Trasplante autólogo de progenitores; Trasplante cardiacoAmyloidosis; Free light chains; N-terminal prohormone of brain natriuretic peptide; Bortezo
Keywords: بورتِـزومیب; Panobinostat; Marizomib; Bortezomib; Acute myeloid leukemia; Multiple myeloma
Keywords: بورتِـزومیب; Bortezomib; Neuroblastoma; Stealth liposomes; Vascular targeting; Targeted therapy;
Keywords: بورتِـزومیب; Mantle cell lymphoma; Relapsed/refractory; Bendamustine; Bortezomib; Ibrutinib; Autologous hematopoietic cell transplant; Allogeneic hematopoietic cell transplantation;
Keywords: بورتِـزومیب; Bortezomib; Copper–zinc superoxide dismutase; Disulfiram; Multiple myeloma; SOD1ATN-224, choline tetrathiomolybdate; BR, BTZ resistant; BTZ, bortezomib; CI, confidence interval; Cu, copper; CuZnSOD, copper–zinc superoxide dismutase; DDC, diethyldithiocarb
Keywords: بورتِـزومیب; Bortezomib; Basal-like triple negative breast cancer; Nanoparticle; Cancer stem cells; Poly(ethylene glycol)-block-poly(d,l-lactide)
Keywords: بورتِـزومیب; BCL-XL; Myc/B cell extra-large; b.i; bone implant; BM; bone marrow; BMD; bone mineral density; Bort; bortezomib; β2M; β2Microglobulin; Car; carfilzomib; CP; cyclophosphamide; Dex; dexamethasone; DKK1; Dickkopf-1; Dox; doxorubicin; GFP; green fluorescent
Keywords: بورتِـزومیب; Proteasome inhibitor; Resistance; Multiple myeloma; Leukemia; Bortezomib
Keywords: بورتِـزومیب; AH; amyloid heavy chain; AL; amyloid light chain; ASCT; autologous stem cell transplant; ATTR; amyloid transthyretin; B-Dex; bortezomib and dexamethasone; BMDex; bortezomib plus melphalan and dexamethasone; BNP; brain natriuretic peptide; Bor; bortezomib;
Keywords: بورتِـزومیب; Proteasome; Bortezomib; Carfilzomib; Ixazomib citrate; MLN9708;
Keywords: بورتِـزومیب; Hematologic malignancies; Dipyridamole; Bortezomib; GSH/ROS; ER stress; Pro-survival pathways; JAK2;
Keywords: بورتِـزومیب; 4-HPR; N-(4-hydroxyphenyl)retinamide; 5â²-UTR; 5â²-untranslated region; 9-cis-RA; 9-cis retinoic acid; 9cUAB30; (2E,4E,6Z,8E)-8-(3â²,4â²-dihydro-1â²(2'H)-naphthalen-1â²-ylidene)-3,7-dimethyl-2,4,6-octatrienoic acid; Acitretin; (2E,4E,6E,8E)-9-(4-met
Keywords: بورتِـزومیب; SDC1; Syndecan-1; Bort; Bortezomib; Dox; Doxorubicin; HGF; Hepatocyte growth factor; IL-11; Interleukin-11; Chemotherapy; Multiple myeloma; Shedding; Shed syndecan-1; Batimastat; Hepatocyte growth factor;
Keywords: بورتِـزومیب; Peripheral neurophathy; Proteasome inhibitors; Neurotoxicity; Bortezomib; Carfilzomib
Keywords: بورتِـزومیب; Bortezomib; Romidepsin; NSCLC